Literature DB >> 1830065

Regulation of alloreactivity in vivo by IL-4 and the soluble IL-4 receptor.

W C Fanslow1, K N Clifford, L S Park, A S Rubin, R F Voice, M P Beckmann, M B Widmer.   

Abstract

Although numerous in vitro studies have demonstrated that cytokines are involved in the generation of alloreactive effector cells, the role of these regulatory substances in vivo is less well defined. We have recently cloned and expressed cDNAs encoding both membrane bound and soluble forms of the murine IL-4R. The effects of murine rIL-4 and a recombinant, soluble, extracellular portion of the murine IL-4R soluble(s) IL-4R on the generation of alloresponsiveness in vivo were evaluated by measuring the lymphoproliferative response to a localized injection of allogeneic cells and the survival of cardiac allografts. Administration of IL-4 to BALB/c mice resulted in a slight augmentation of the anti-C57BL/6 lymphoproliferative response compared to that occurring in control, mouse serum albumin-(MSA) treated mice. In contrast, the sIL-4R suppressed this response to allogeneic cells in a dose-dependent manner, with a dose of 50 micrograms/kg/day causing nearly complete inhibition of the response as compared to the response observed in controls. The inhibitory effect of sIL-4R was reversed by simultaneous administration of IL-4. A neutralizing antibody against IL-4 (11B11) and another against the IL-4R (M1) were also effective inhibitors of the response when given at 100- to 1000-fold higher concentrations than the amount of sIL-4R required to inhibit the response. In cardiac allograft experiments, BALB/c mice were engrafted with newborn C57BL/6 hearts in the ear pinnae and treated with sIL-4R (50 micrograms/kg) or MSA. Such allografts survived an average of 4 days longer in sIL-4R-treated mice than in MSA-treated controls. In conclusion, neutralization of IL-4 inhibits alloresponsiveness in vivo. These results confirm a regulatory role for this pleiotropic cytokine in allograft rejection and suggest a therapeutic value for IL-4 antagonists alone or in combination with other immunosuppressive regimens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1830065

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Allograft rejection results from a failed attempt by the immune system to protect foreign tissue.

Authors:  D S Hall; E Roberts; J Davies
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

2.  IL-4 expression delays eosinophil-independent vasculopathy and fibrosis during allograft rejection in the mouse.

Authors:  Edda M Roberts; De Shon Hall; Sharon Ferguson; Susan Minson; Joanna D Davies
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

Review 3.  Cytokines. 3. Cytokines in asthma.

Authors:  D S Robinson; S R Durham; A B Kay
Journal:  Thorax       Date:  1993-08       Impact factor: 9.139

4.  Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses.

Authors:  V A Varney; Q A Hamid; M Gaga; S Ying; M Jacobson; A J Frew; A B Kay; S R Durham
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

5.  Interleukin-4 receptor alpha-deficient BALB/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infection.

Authors:  M Mohrs; C Holscher; F Brombacher
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

6.  Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice.

Authors:  H Ghiasi; Y Osorio; G C Perng; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

7.  Recombinant soluble interleukin-4 (IL-4) receptor acts as an antagonist of IL-4 in murine cutaneous Leishmaniasis.

Authors:  A Gessner; K Schröppel; A Will; K H Enssle; L Lauffer; M Röllinghoff
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

8.  New immunosuppressive drugs: needs in and applications to pediatric transplantation.

Authors:  B D Kahan
Journal:  Eur J Pediatr       Date:  1992       Impact factor: 3.183

9.  A role for IL-4 in immunologically mediated enteropathy.

Authors:  A M Mowat; M B Widmer
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

10.  Role of IL-2 and IL-4 in exacerbations of murine antigen-induced arthritis.

Authors:  M J Jacobs; A E van den Hoek; P L van Lent; F A van de Loo; L B van de Putte; W B van den Berg
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.